The UK’s Medicines and Healthcare Regulatory Agency has approved GenSight Biologics‘ (EPA:SIGHT) application to combine gene therapy and a wearable optronic visual stimulation device in patients with retinitis pigmentosa.
The first-in-man Phase I/II trial is designed to study the safety and tolerability of GenSight’s GS030 combination therapy in three groups of three patients each.
Get the full story at our sister site, Drug Delivery Business News.
The post GenSight to launch trial of gene therapy, visual stimulation device combo in UK appeared first on MassDevice.